INmune Bio Presents New Phase 1 Study Data Demonstrating Dose-Dependent Effect Of XPro On Proteins That Regulation Synapses In Alzheimer's Patients In AAIC Poster Presentation
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. (NASDAQ: INMB) presented new Phase 1 study data at the Alzheimer's Association International Conference (AAIC) demonstrating the dose-dependent effect of their drug XPro on synaptic proteins in Alzheimer's patients.
July 29, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio Inc. presented new Phase 1 study data at AAIC showing XPro's dose-dependent effects on synaptic proteins in Alzheimer's patients, which could indicate potential efficacy in treating the disease.
The presentation of positive Phase 1 data at a major conference like AAIC can boost investor confidence in INmune Bio's pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100